Network | Number of trials that did not change any treatment rank (%) | Among studies that impacted treatment’s ranks… | ||||||
Median of observed kappas (κ) (minimum, maximum) | Treatments* | Number (%) of studies displacing treatment’s rank by… | ||||||
Unweighted | Weighted | 1 rank | 2 ranks | 3 ranks | 4 ranks | |||
COPD21 | 30 (76.9%) | 71% (14%, 71%) | 98% (81%, 98%) | Tiotropium | 3 (33%) | 0 (0%) | 0 (0%) | 0 (0%) |
Budesonide+formoterol | 3 (33%) | 0 (0%) | 0 (0%) | 0 (0%) | ||||
Fluticasone+salmeterol | 1 (11%) | 0 (0%) | 0 (0%) | 0 (0%) | ||||
Budesonide | 4 (44%) | 0 (0%) | 2 (22%) | 0 (0%) | ||||
Salmeterol | 5 (56%) | 0 (0%) | 0 (0%) | 0 (0%) | ||||
Fluticasone | 2 (22%) | 0 (0%) | 0 (0%) | 0 (0%) | ||||
Formoterol | 4 (44%) | 0 (0%) | 0 (0%) | 0 (0%) | ||||
Placebo | 2 (22%) | 1 (11%) | 0 (0%) | 0 (0%) | ||||
Depression22 | 36 (32.4%) | 82% (45%, 82%) | 99% (89%, 99%) | Mirtazapine | 1 (1%) | 0 (0%) | 0 (0%) | 0 (0%) |
Escitalopram | 2 (3%) | 0 (0%) | 0 (0%) | 0 (0%) | ||||
Venlafaxine | 2 (3%) | 0 (0%) | 0 (0%) | 0 (0%) | ||||
Sertraline | 1 (1%) | 0 (0%) | 0 (0%) | 0 (0%) | ||||
Citalopram | 3 (4%) | 0 (0%) | 0 (0%) | 0 (0%) | ||||
Bupropion | 3 (4%) | 0 (0%) | 0 (0%) | 0 (0%) | ||||
Milnacipran | 13 (17%) | 1 (1%) | 1 (1%) | 1 (1%) | ||||
Paroxetine | 19 (25%) | 0 (0%) | 0 (0%) | 0 (0%) | ||||
Fluoxetine | 37 (49%) | 21 (28%) | 0 (0%) | 0 (0%) | ||||
Duloxetine | 61 (81%) | 3 (4%) | 2 (3%) | 0 (0%) | ||||
Fluvoxamine | 30 (40%) | 7 (9%) | 1 (1%) | 2 (3%) | ||||
Reboxetine | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | ||||
Diabetes23 | 21 (95.5%) | 60% (60%, 60%) | 94% (94%, 94%) | Angiotensin- receptor blockers | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) |
Angiotensin-converting- enzyme inhibitors | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | ||||
Placebo | 1 (100%) | 0 (0%) | 0 (0%) | 0 (0%) | ||||
Calcium-channel blockers | 1 (100%) | 0 (0%) | 0 (0%) | 0 (0%) | ||||
β blocker | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | ||||
Diuretic | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | ||||
Heavy menstrual bleeding24 | 16 (80%) | 33% (0%, 33%) | 80% (40%, 80%) | Hysterectomy | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) |
Mirena | 3 (75%) | 1 (0%) | 0 (0%) | 0 (0%) | ||||
2nd generation endometrial destruction | 4 (100%) | 0 (0%) | 0 (0%) | 0 (0%) | ||||
1st generation endometrial destruction | 1 (25%) | 0 (0%) | 0 (0%) | 0 (0%) | ||||
Stroke25 | 26 (100%) | N/A | N/A | Aspirin+dipyridamole | N/A | |||
Thienopyridines+aspirin | ||||||||
Thienopyridines | ||||||||
Aspirin | ||||||||
Control |
*Treatments listed in order of SUCRA-based rank computed from NMA of complete data set.
COPD, chronic obstructive pulmonary disease; N/A, Not applicable; NMA, network meta-analysis; SUCRA, Surface Under the Cumulative RAnking curve.